Biktarvy

spinqualitylabelsall models Caption for this structure Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Bictegravir/emtricitabine/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide. It was approved for use in the United States in February 2018, and for use in the European Union in June 2018. Bictegravir (integrase inhibitor): Structure of the STLV intasome:B56 complex bound to the strand-transfer inhibitor bictegravir (7ouh). Bictegravir inhibits integrase. Emtricitabine (nucleotide reverse transcriptase inhibitor): Emtricitabine. Emtricitabine binding site at reverse transcriptase (2no6). Water molecules are shown as red spheres. Tenofovir alafenamide (nucleotide reverse transcriptase inhibitor): Tenofovir alafenamide.

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky